

Washington University School of Medicine

Digital Commons@Becker

---

2020-Current year OA Pubs

Open Access Publications

---

1-1-2023

## Objective response to immune checkpoint inhibitor therapy in NRAS-mutant melanoma: A systematic review and meta-analysis

Zachary J Jaeger

Neel S Raval

Natalia K A Maverakis

David Y Chen

George Ansstas

*See next page for additional authors*

Follow this and additional works at: [https://digitalcommons.wustl.edu/oa\\_4](https://digitalcommons.wustl.edu/oa_4)

 Part of the [Medicine and Health Sciences Commons](#)

Please let us know how this document benefits you.

---

---

**Authors**

Zachary J Jaeger, Neel S Raval, Natalia K A Maverakis, David Y Chen, George Ansstas, Angela Hardi, and Lynn A Cornelius



## OPEN ACCESS

EDITED BY  
Antonio Ji-Xu,  
University of California, Davis,  
United States

REVIEWED BY  
Zhenwei Tang,  
Zhejiang University School of Medicine,  
China  
Stephanie T. Le,  
University of California, Davis,  
United States

\*CORRESPONDENCE  
Zachary J. Jaeger  
✉ zjaeger@wustl.edu

SPECIALTY SECTION  
This article was submitted to  
Dermatology,  
a section of the journal  
Frontiers in Medicine

RECEIVED 05 November 2022  
ACCEPTED 25 January 2023  
PUBLISHED 16 February 2023

CITATION  
Jaeger ZJ, Raval NS, Maverakis NKA, Chen DY,  
Ansstas G, Hardi A and Cornelius LA (2023)  
Objective response to immune checkpoint  
inhibitor therapy in *NRAS*-mutant melanoma: A  
systematic review and meta-analysis.  
*Front. Med.* 10:1090737.  
doi: 10.3389/fmed.2023.1090737

COPYRIGHT  
© 2023 Jaeger, Raval, Maverakis, Chen,  
Ansstas, Hardi and Cornelius. This is an open-  
access article distributed under the terms of  
the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in  
other forums is permitted, provided the original  
author(s) and the copyright owner(s) are  
credited and that the original publication in this  
journal is cited, in accordance with accepted  
academic practice. No use, distribution or  
reproduction is permitted which does not  
comply with these terms.

# Objective response to immune checkpoint inhibitor therapy in *NRAS*-mutant melanoma: A systematic review and meta-analysis

Zachary J. Jaeger<sup>1\*</sup>, Neel S. Raval<sup>1</sup>, Natalia K. A. Maverakis<sup>2</sup>,  
David Y. Chen<sup>3,4</sup>, George Ansstas<sup>3</sup>, Angela Hardi<sup>1</sup> and  
Lynn A. Cornelius<sup>3,4</sup>

<sup>1</sup>Office of Medical Student Education, Washington University School of Medicine, St. Louis, MO, United States, <sup>2</sup>San Juan Bautista School of Medicine, Caguas, PR, United States, <sup>3</sup>Alvin J. Siteman Comprehensive Cancer Center, Washington University School of Medicine, St. Louis, MO, United States, <sup>4</sup>Division of Dermatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States

**Introduction:** *NRAS* mutations are common in melanoma and confer a worse prognosis. Although most patients with metastatic melanoma receive immune checkpoint inhibitors (ICIs), the impact of *NRAS* mutational status on their efficacy remains under debate.

**Methods:** We performed a comprehensive literature search across several large databases. Inclusion criteria were trials, cohorts, and large case series that analyzed the primary outcome of objective response rate by *NRAS* mutational status in patients with melanoma treated with any line of ICI. At least two reviewers independently screened studies using Covidence software, extracted data, and assessed risk of bias. Standard meta-analysis was performed in R with sensitivity analysis and tests for bias.

**Results:** Data on 1770 patients from ten articles were pooled for meta-analysis, and the objective response rate to ICIs was calculated to compare *NRAS*-mutant and *NRAS*-wildtype melanoma. The objective response rate was 1.28 (95% confidence interval: 1.01–1.64). Sensitivity analysis identified the study by Dupuis et al. with influential impact on the pooled effect size and heterogeneity, favoring *NRAS*-mutant melanoma.

**Discussion:** In this meta-analysis evaluating the impact of *NRAS* mutational status on objective response to ICIs in metastatic melanoma, *NRAS*-mutant cutaneous melanoma demonstrated an increased likelihood of partial or complete tumor response, relative to *NRAS*-wildtype cutaneous melanoma. Genomic screening for *NRAS* mutations in patients with metastatic melanoma may improve predictive ability when initiating ICIs.

## KEYWORDS

metastatic melanoma, cutaneous melanoma, immunotherapy, checkpoint inhibitor, *NRAS*, objective response rate, disease control rate, *NRAS*-mutant melanoma

## 1. Introduction

Melanoma is the sixth-leading cause of cancer diagnosis in the United States and is responsible for the most deaths from skin cancer (1). The Surveillance, Epidemiology, and End Results database indicates that incidence of cutaneous melanoma has increased over the past two decades (2). Whereas

FDA approval of multiple immune checkpoint inhibitors (ICIs) in the past decade has revolutionized therapy, five-year survival still hovers around 30% for metastatic melanoma (2–6). While new strategies are being investigated, we are interested in understanding whether and why molecular subtypes of melanoma may respond differently to ICIs (7).

The contemporaneous emergence of next-generation sequencing has improved our abilities to characterize individual patients' melanomas and to research potential genetic targets. *NRAS* mutations are present in approximately 20% of all melanomas and portend a worse prognosis than does *NRAS*-wildtype status (8, 9). Although the lack of effective targeted therapy makes *NRAS*-mutant melanoma a more controversial subtype than *BRAF*-mutant melanoma, studies suggest that *NRAS* mutational status is an independent prognostic factor for metastatic melanoma and may be associated with immunotherapy response (9–15). Immunotherapy is considered the standard of care for most patients with locally advanced or metastatic melanoma without a contraindication, but their comparative efficacy in *NRAS*-mutant versus *NRAS*-wildtype melanoma remains unclear (9, 10). Some studies have suggested that in advanced melanoma treated with ICIs, *NRAS*-mutation-positive status is associated with higher rates of tumor objective response and/or prolonged survival (16, 17), while others do not support this association (18, 19). To our knowledge, a comprehensive synthesis of the available evidence of the outcomes of ICIs for melanoma based on *NRAS* mutational status has not been undertaken.

Therefore, we conducted a systematic review and meta-analysis to critically appraise and synthesize the published data comparing objective response rate (ORR) to ICIs by *NRAS* mutational status in patients with melanoma.

## 2. Manuscript

### 2.1. Methods

This systematic review was registered in the PROSPERO database (ID: CRD42021273588) and reported according to PRISMA and MOOSE guidelines. The Washington University Institutional Review Board determined this project to be non-human subjects research.

#### 2.1.1. Search strategy

A clinical librarian (AH) executed a comprehensive search in PubMed, Embase, Scopus, Web of Science, Cochrane Library (including CENTRAL), and [Clinicaltrials.gov](https://clinicaltrials.gov) databases from database origin to 14 June 2022. The full search strategy is available in the Supplementary Materials. Results were limited to English and human studies.

Two reviewers independently screened titles and abstracts for eligibility (ZJJ, NSR) and, subsequently, relevant full texts (ZJJ, NSR) using the Covidence systematic review management program (20). One reviewer performed forward and reverse citation searches (ZJJ), i.e., screenings of articles citing and cited by included studies, respectively.

Two or three reviewers independently extracted data (ZJJ, NSR, NKAM). Disagreements were resolved by consensus.

#### 2.1.2. Eligibility criteria

We included randomized, controlled trials and cohort studies that analyzed ORR by *NRAS* mutational status in patients with melanoma treated with any line of ICI. We excluded unpublished work, gray literature, duplicate studies, animal studies, *in vitro* studies, case reports, expert opinions, and reviews.

The primary outcome was ORR for *NRAS*-mutant and *NRAS*-wildtype melanoma, defined as the percentage of patients with complete (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors v1.1 or immune-related response criteria at the time of last follow-up (21, 22). We defined the comparison group as either confirmed to be triple-negative for *NRAS*, *BRAF*, and *NF1* mutations or at least confirmed *NRAS*-wildtype; if comparison groups included melanoma with other mutations, previous or current targeted therapy merited exclusion. If the genotype data were not explicitly stated, we contacted authors for clarification. Patients with stable (SD) or progressive disease (PD) were considered unresponsive to treatment. A secondary outcome was the disease control rate (DCR), denoted by the percentage of patients with CR, PR, or SD. Other extracted data included patient sex and age, melanoma subtype, stage at ICI initiation, ICI class and line, and tumor mutational burden (TMB).

#### 2.1.3. Quality assessment

Three reviewers (ZJJ, NSR, and NKAM) independently assessed the overall quality of evidence of each study *via* the Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence and modified Newcastle-Ottawa scale (mNOS) (23, 24). We designated OCEBM study quality per the “Therapy/Prevention, Aetiology/Harm” category from 1a (best) to 5 (poorest), with mNOS scored from 0 (poorest) to 9 (best). To test for potential publication bias, we visually inspected a contour-enhanced funnel plot, graphically evaluated using the trim-and-fill method (25), and statistically evaluated with the Egger regression test (26).

#### 2.1.4. Data synthesis and statistical analysis


We used R version 4.1.2 (packages “metafor” and “metaviz”) for all data analysis. We performed a meta-analysis of the pooled relative risk ratios of ORR of cutaneous melanoma using a random-effects model. The Yates correction was employed for cells with zero to estimate the 95% confidence intervals (CI). The results were plotted on a forest plot with 95% CI of the relative risk ratios of ORR. We evaluated heterogeneity between studies with the  $I^2$  statistic (greater than 50% suggesting moderate heterogeneity) and Q statistic (greater than the degrees of freedom suggesting significant heterogeneity). We repeated these methods for DCR. A sensitivity analysis was performed to identify influential studies in the ORR meta-analysis.

## 2.2. Results

### 2.2.1. Literature search

After removal of duplicates, 473 records were screened, 157 full-text articles were assessed, and 16 studies met inclusion criteria for the systematic review, with 10 of those being amenable to meta-analysis (Figure 1) (16, 18, 19, 27–39). Data on 1770 patients from two prospective studies and eight retrospective cohort studies were pooled for analysis.

Abbreviations: ICI, immune checkpoint inhibitor; ORR, objective response rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; DCR, disease control rate; TMB, tumor mutational burden; CI, confidence interval; RR, relative risk; OCEBM, Oxford Centre for Evidence-based Medicine; mNOS, modified Newcastle-Ottawa scale; ALM, acral lentiginous melanoma.



## 2.2.2. Study characteristics

Most included studies were retrospective cohorts and took place in the 2010s in North America, Europe, and Asia (Table 1). Three of four prospective trials were carried out in Asia, with the other trial by Ascierio et al. occurring in Italy (27, 33, 35, 38). Participants were generally middle-aged adults with an approximate pooled median of 55–65 years, with a slight male predominance (54%). Cutaneous melanoma was the predominant subtype in 11 studies, with varying prevalence of non-cutaneous subtypes (mucosal, acral, uveal, and unknown primary) comprising the remainder. Most of the studies of patients with non-cutaneous melanoma occurred in Asia; these studies were included for the systematic review but excluded from meta-analysis (33, 35, 36, 38). All studies involved patients with metastatic melanoma, many with predominantly Stage IV (78% among those reporting stage). ICI regimens varied, ranging from anti-CTLA-4 (8/16, 50%) or anti-PD-1/PD-L1 monoclonal antibody (14/16, 88%) monotherapy to combinations thereof (5/16, 31%), some combined with chemotherapy (3/16, 19%). Only five studies included patients on combination ICI therapy, ranging from 1 to 40% of the study population. Data were unavailable for individual participants by mutational status, precluding subgroup analysis by ICI line and class.

## 2.2.3. Meta-analysis

For the ten included studies encompassing 1770 participants, the pooled relative risk ratio (RR) of ORR by *NRAS* mutational status was 1.28 (95% CI: 1.01–1.64). The  $I^2$  statistic was 53%, indicating moderate-to-high heterogeneity, and  $Q$  ( $df=9$ ) was 17 ( $p=0.05$ ). The meta-analysis of ORR is graphically represented in a rainforest plot in Figure 2.

There were eight studies reporting DCR for 1,650 patients with metastatic cutaneous melanoma. The pooled RR by *NRAS* mutational status was 1.11 (95% CI: 0.87–1.41). There was moderate-to-high

heterogeneity, with  $I^2$  at 79% (95% CI: 44–97) and  $Q$  ( $df=7$ ) at 28 ( $p=0.0002$ ). The three studies in the ORR meta-analysis that did not provide DCR data reported RRs of 1.70, 2.21, and 2.72, favoring *NRAS*-mutant melanoma (29, 32, 34). The meta-analysis of DCR is graphically represented in a rainforest plot in Figure 3.

## 2.2.4. Sensitivity analysis

Leave-one-out sensitivity analysis of ORR produced overall effect sizes ranging from 1.16 to 1.38 (lower bound of 95% CI: 0.96–1.05; upper bound: 1.40–1.83). The  $I^2$  statistic ranged from 27 to 61%, and  $Q$  ranged from 11.3 to 16.9. Omission of the study by Zhang et al. maximized the lower bound at 1.05, greater than the null RR of 1 (39). Individual omission of the study by Dupuis et al. minimized  $I^2$  to 27% and the 95% CI bounds to 0.96 and 1.40 (26); it also minimized the pooled estimate to 1.16(), while the remainder ranged from 1.20() to 1.38 (32, 34, 39).

## 2.2.5. Quality assessment and risk of publication bias

Oxford Centre for Evidence-Based Medicine quality ratings (Table 1) ranged from 2b to 4, with all earning a grade of 2b except the case series (28). mNOS ranged from 7 to 9 indicating generally low risk of bias, except for the case series (4). Inspection of the contour-enhanced funnel plot of the ORR meta-analysis revealed some asymmetry, with larger studies tending to report positive effect sizes and one small study reporting a non-significant negative result. The trim-and-fill method imputed two moderate-to-large studies, one with a non-significant negative effect size, the other on the borderline of significance, and the Egger regression test was statistically significant for asymmetry ( $p=0.02$ ). The Baujat plot identified the study by Dupuis et al. (32, 40) and as particularly influential on the overall results. Graphical representations of statistical tests for bias are included in the Supplementary material.

## 2.2.6. Tumor mutational burden

Six studies reported outcome data on TMB (29, 33, 35–37, 39). Four of these reported increased ORR in higher-TMB groups ranging from 30 to 85%, with only Johnson et al.'s (29, 33, 35–37) paper achieving statistical significance (85%,  $p<0.001$ ). Byeon et al. (36) reported better one-year progression-free survival for the higher-TMB group on ICIs at approximately 45 vs. 30%, though it was not quite statistically significant ( $p=0.051$ ). Zhang et al. (39) found higher TMB associated with prolonged overall survival ( $p<0.001$ ).

## 2.3. Discussion

The seminal paper by Johnson et al. (16) in 2015 supported positive *NRAS* mutational status as a predictor of good response to ICIs. In 2018, Dupuis et al. (32) also found an increased ORR for *NRAS*-mutant melanoma. That same year, however, Kirchberger et al. (18) demonstrated equivocal predictive value of *NRAS* mutational status. In 2021, Guida et al. (19) explored this hypothesis further and discovered a similar questionable effect with non-significant confidence intervals. In contribution to the debate surrounding the effect of the *NRAS* mutational status of melanoma on ICI response, this meta-analysis demonstrated a benefit for *NRAS*-mutant cutaneous melanoma (RR 1.28), i.e., a higher ICI response rate was seen for *NRAS*-mutant melanoma relative to wildtype. Implications of this conclusion could include, for instance,

TABLE 1 Summary data and quality assessment.


Author	Year	Country	Study type	Female, <i>n</i> (%)	Age (in years)	Predominant melanoma type	Class of ICI <sup>a</sup>	OCEBM/mNOS Quality <sup>b</sup>
Ascierto et al.	2014	Italy	Prospective cohort	395 (46)	Median 61, Min-max <sup>c</sup> 16–88	Cutaneous	Anti-CTLA-4 monotherapy	2b/7
Lipson et al.	2014	United States	Case series	4 (50)	Median 58, Min-max 43–79	Cutaneous	Anti-CTLA-4 or anti-PD-L1 monotherapy	4/4
Johnson et al.	2015	United States	Retrospective cohort	50 (28)	61% 60+	Cutaneous	Anti-PD-1, anti-PD-L1, anti-CTLA-4, or IL-2 monotherapy	2b/8
Johnson et al.	2016	United States	Retrospective cohort	27 (42)	Initial: Median 55, Min-max 33–80; Validation: Median 62, Min-max 32–85	Cutaneous	Anti-PD-1 or anti-PD-L1 monotherapy	2b/8
Jamal et al.	2017	Canada	Prospective cohort	8 (27)	Median 55, Min-max 26–74	Cutaneous	Anti-CTLA-4 monotherapy	2b/7
Afzal et al.	2018	United States	Retrospective cohort	21 (38)	Mean 63, SD <sup>d</sup> 15	Cutaneous	Anti-PD-1 monotherapy or anti-CTLA-4/anti-PD-1 combination therapy	2b/9
Dupuis et al.	2018	France	Retrospective cohort	29 (41)	61% 60+	Cutaneous	Anti-PD-1 monotherapy	2b/8
Kirchberger et al.	2018	Germany	Retrospective cohort	154 (42)	Median 64, Min-max 20–87	Cutaneous	Anti-CTLA-4 or anti-PD-1 monotherapy or combination therapy	2b/8
Sheng et al.	2019	China	Phase 1B clinical trial	20 (61)	Median 54, Min-max 27–70	Mucosal	Anti-PD-1 monotherapy	2b/7
Loo et al.	2020	United States	Retrospective cohort	22 (33)	Median 59, Min-max 27–93	Cutaneous	Anti-CTLA-4 or anti-PD-1 monotherapy or combination therapy	2b/7
Tang et al.	2020	China	Phase 2 clinical trial	70 (55)	Mean 52, SD 11	Acral, mucosal	Anti-PD-1 monotherapy	2b/7
Byeon et al.	2021	Korea	Retrospective cohort	90 (51)	Median 61, Min-max 23–84	Acral, cutaneous, mucosal	Anti-PD-1 monotherapy	2b/8
Guida et al.	2021	Italy	Retrospective cohort	127 (38)	<i>NRAS</i> +: Median 63, IQ <sup>e</sup> min-max 53–74; <i>NRAS</i> -: Median 65, IQ min-max 54–73	Cutaneous	Anti-PD-1 or anti-CTLA-4 monotherapy or combination therapy	2b/9
Li et al.	2021	China	Retrospective cohort	32 (50)	Median 54, Min-max 25–72	Cutaneous	Anti-PD-1 monotherapy	2b/8
Zhou et al.	2021	China	Prospective trials	119 (58)	15% 65+	Non-cutaneous, cutaneous	Anti-PD-1 monotherapy	2b/9
Zhang et al.	2022	International	Retrospective cohort	199 (36)	51% 61+	Cutaneous	Anti-CTLA-4, anti-PD-1, or anti-PD-L1 monotherapy or combination therapy	2b/8

<sup>a</sup>ICI: immune checkpoint inhibitor. <sup>b</sup>OCEBM Quality Assessment: Oxford Centre for Evidence-based Medicine Levels of Evidence; NOS: modified Newcastle-Ottawa scale. <sup>c</sup>Min-max: minimum to maximum. <sup>d</sup>SD: standard deviation. <sup>e</sup>IQ: interquartile.


increased pertinence of *NRAS* mutational status ordering for patients with newly diagnosed metastatic cutaneous melanoma, or increased likelihood of initiating ICIs in metastatic cutaneous melanoma found to harbor an *NRAS* mutation. Further research into the potential immunological mechanism should continue to be explored. Interestingly,

the results for DCR were lower and centered around the null; this could be partially explained by the exclusion of three studies with positive RR for ORR that did not report data for DCR.

Quality ratings of included studies were consistent with observational data. The funnel plot and trim-and-fill method indicated



**FIGURE 2** Forest plot of the random-effects meta-analysis for relative risk ratios of objective response rates (ORR) of cutaneous melanoma by *NRAS* mutational status. *NRAS*-mut: *NRAS*-mutant melanoma; *NRAS*-wt: *NRAS*-wildtype melanoma; OR: Objective response; NR: No objective response.



**FIGURE 3** Forest plot of the random-effects meta-analysis for relative risk ratios of disease control rates (DCR) of cutaneous melanoma by *NRAS* mutational status. *NRAS*-mut: *NRAS*-mutant melanoma; *NRAS*-wt: *NRAS*-wildtype melanoma; DC: Disease control; PD: Progressive disease.

moderate concern for significant publication bias, and the Egger regression test supported the presence of asymmetry. Sources of bias such as heterogeneity between subgroups, selective outcome reporting, or chance, could be contributing to asymmetry of the funnel plot (41). In further exploration of heterogeneity, the Baujat plot indicated that the study by Dupuis et al. exerted disproportionate influence on the meta-analysis, and the sensitivity analysis was consistent with its impact on both the pooled effect size and heterogeneity measures (32). Taken together, the overall certainty of the evidence for ORR was rated as moderate (42).

The included studies largely assessed cutaneous melanoma patients based in Europe and the United States and excluded non-cutaneous

melanoma studies due to their relative paucity and to avoid unlike comparisons. The few non-cutaneous-predominant studies by Sheng et al., Tang et al., Byeon et al., and Zhou et al. (33, 35, 36, 39) generally reported low ORR for *NRAS*-mutant melanoma. It is well known that non-cutaneous melanoma subtypes carry unique mutation patterns distinct from ultraviolet radiation-related signatures and often respond poorly to current therapies (43–45). Further investigation of this diverse population is warranted to better guide therapy and improve outcomes (46, 47).

The collected literature offers several potential explanations for the observed effects of ICIs on *NRAS*-mutant melanoma. Johnson et al. conducted a separate analysis which found higher PD-L1

expression in *NRAS*-mutant melanoma, though this failed to reach significance and other larger cohorts have not found PD-L1 expression to necessarily be consequential to ICI response (16, 48). In contrast, Byeon et al. (36) speculated *NRAS*-mutant melanoma could be associated with ICI resistance, perhaps due to alterations in cell surface proteins necessary for T-cell response similar to *TP53*-mutant tumors. Still others have hypothesized a synergistic effect of MAP kinase and ICI due to greater melanoma antigen production, though these preclinical findings need further real-world confirmation (49). Interestingly, in a subset of *NRAS*-mutant melanoma patients receiving immunotherapy, a frequently co-occurring PBAF complex mutation was associated with greater progression-free and overall survival (50). Most frequently, however, authors posit that TMB may be central to the ICI-*NRAS* interaction.

Quantifying TMB has become more critical in understanding cancer therapeutics and may help predict ICI response. In theory, higher TMB produces a greater degree of passenger mutations, increasing tumor neoantigenicity, T-lymphocyte infiltration, and antitumor immune response (7, 48, 51). A large-scale retrospective analysis of several primary tumor types found that TMB status may explain 55% of ORR variation to ICIs (52). Similarly, CheckMate 067 trial data revealed ICI responders were more likely to have higher TMB and higher inflammatory signatures than non-responders (53). Six studies included in this meta-analysis reported TMB data associating higher TMB with higher ORR, though an accurate pooled effect cannot be calculated here (29, 33, 35–37, 39). A meta-analysis that focuses on the role of TMB on melanoma outcomes in patients initiating ICIs is needed.

*NRAS*-mutant melanoma has proven challenging to treat, especially for those unresponsive to immunotherapy. The *NRAS* protein itself is difficult to target directly, and upstream and downstream effectors have demonstrated equivocal efficacy, with a few showing promise (9). Although testing is available from commercial entities, it may not be routinely performed due to a lack of effective target therapy. MEK inhibitors, alone or in combination with pan-RAF, CDK4/6, or focal adhesion kinase inhibitors, are under investigation in clinical trials for metastatic *NRAS*-mutant melanoma (14). Others are studying the predictive value of biomarkers and genomic profiles that might shed light on subpopulations more or less responsive to certain immunotherapy regimens (54, 55). One study identified *NF1* mutational status as a predictor of poor response (56), while another found good tumor response in *NF1*-mutant melanoma (57); clearly, there is a need for further investigation. Indeed, the field of melanoma continues to head toward a “multiomics”-driven approach to mutational and molecular-level stratification that could reveal predictors of therapeutic response or novel targets and treatments (58–60).

### 2.3.1. Limitations

The review presented several challenges. Despite a sensitive literature search, the dearth of eligible articles, combined with the novelty of ICIs, resulted in a relatively small number of included studies. Some heterogeneity among variables and outcomes of interest was present, leading to possible reporting bias. This was partially mitigated by some authors responding to share supplementary data, but with more administrative resources, a meta-analysis with individual participant data and meta-regression would

better characterize subgroups and adjust for potentially confounding variables.

### 2.3.2. Conclusion

Melanoma is a leading cause of cancer diagnosis in the United States and a diagnosis that dermatologists frequently encounter in both inpatient and outpatient settings. At high stages, prognosis is poor, and even more so when *NRAS* mutational status is positive. In this meta-analysis comparing objective response to ICI therapy between *NRAS*-mutant and *NRAS*-wildtype metastatic melanoma, there was an increased likelihood of response for *NRAS*-mutant cutaneous melanoma. Genomic screening for patients diagnosed with metastatic melanoma may improve predictive ability for those harboring *NRAS* mutations. In the era of precision medicine with checkpoint inhibition and combination therapies, more prospective research on all types of melanoma is warranted, especially randomized, controlled trials on *NRAS* mutational status reporting complete demographics, molecular data, tumor response, and survival outcomes.

## Data availability statement

Publicly available datasets were analyzed in this study. This data can be found at: <https://pubmed.ncbi.nlm.nih.gov/24885479/>; <https://pubmed.ncbi.nlm.nih.gov/33399091/>; <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048096/>; <https://pubmed.ncbi.nlm.nih.gov/33530579/>; <https://pubmed.ncbi.nlm.nih.gov/29157311/>; <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351797/>; <https://pubmed.ncbi.nlm.nih.gov/27671167/>; <https://pubmed.ncbi.nlm.nih.gov/29843107/>; <https://pubmed.ncbi.nlm.nih.gov/34181096/>; <https://pubmed.ncbi.nlm.nih.gov/25516806/>; <https://pubmed.ncbi.nlm.nih.gov/32564504/>; <https://pubmed.ncbi.nlm.nih.gov/31403867/>; <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787219/>; <https://pubmed.ncbi.nlm.nih.gov/29966520/>; <https://pubmed.ncbi.nlm.nih.gov/34290710/>; <https://pubmed.ncbi.nlm.nih.gov/32321714/>.

## Author contributions

ZJ, NR, DC, GA, and LC: study conception and design. ZJ, NR, NM, AH, and LC: data collection. ZJ, NR, NM, DC, GA, and LC: analysis and interpretation of results and draft manuscript preparation. All authors meet ICMJE criteria for authorship, and all those who meet ICMJE criteria are listed as authors. All authors contributed to the article and approved the submitted version.

## Funding

Discretionary research funds received from the Division of Dermatology, John T. Milliken Department of Medicine, Washington University School of Medicine in St. Louis.

## Acknowledgments

The authors wish to thank Graham Colditz and Carrie Stoll for their helpful advice and instructional guidance in the initial design of the review, as well as Sierra Jaeger for assistance with R is a statistical analysis software: <https://www.r-project.org/about.html>.



## Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## Supplementary material

The Supplementary material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fmed.2023.1090737/full#supplementary-material>

## References

1. U.S. Cancer Statistics Working Group. U.S. Cancer statistics data visualizations tool, based on 2021 submission data (1999–2019): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. (2022) Available at: [www.cdc.gov/cancer/dataviz](http://www.cdc.gov/cancer/dataviz), released in June 2022. Accessed June 20, 2022.
2. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: melanoma of the skin. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. (2022) Available at: <https://seer.cancer.gov/statfacts/html/melan.html>. Accessed June 20, 2022.
3. Hodi, FS, O'day, SJ, McDermott, DF, Weber, RW, Sosman, JA, Haanen, JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med*. (2010) 363:711–23. doi: 10.1056/NEJMoa1003466
4. Wolchok, JD, Chiarion-Sileni, V, Gonzalez, R, Rutkowski, P, Grob, JJ, Cowey, CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. *N Engl J Med*. (2017) 377:1345–56. doi: 10.1056/NEJMoa1709684
5. Kuryk, L, Bertinato, L, Staniszewska, M, Pancer, K, Wiczorek, M, Salmaso, S, et al. From conventional therapies to immunotherapy: melanoma treatment in review. *Cancers (Basel)*. (2020) 12:3057. doi: 10.3390/cancers12103057
6. Meric-Bernstam, F, Larkin, J, Taberner, J, and Bonini, C. Enhancing anti-tumour efficacy with immunotherapy combinations. *Lancet*. (2021) 397:1010–22. doi: 10.1016/S0140-6736(20)32598-8
7. Maleki, VS. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. *J Immunother Cancer*. (2018) 6:157. doi: 10.1186/s40425-018-0479-7
8. Akbani, R, Akdemir, KC, Aksoy, BA, Albert, M, Ally, A, Amin, SB, et al. Genomic classification of cutaneous melanoma. *Cells*. (2015) 161:1681–96. doi: 10.1016/j.cell.2015.05.044
9. Khaddour, K, Maahs, L, Avila-Rodriguez, AM, Maamar, Y, Samaan, S, and Anstas, G. Melanoma targeted therapies beyond BRAF-mutant melanoma: potential druggable mutations and novel treatment approaches. *Cancers (Basel)*. (2021) 13:5847. doi: 10.3390/cancers13225847
10. Boespflug, A, Caramel, J, Dalle, S, and Thomas, L. Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date. *Ther Adv Med Oncol*. (2017) 9:481–92. doi: 10.1177/1758834017708160
11. Jakob, JA, Bassett, RL Jr, Ng, CS, Curry, JL, Joseph, RW, Alvarado, GC, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. *Cancer*. (2012) 118:4014–23. doi: 10.1002/cncr.26724
12. Devitt, B, Liu, W, Salemi, R, Wolfe, R, Kelly, J, Tzen, CY, et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. *Pigment Cell Melanoma Res*. (2011) 24:666–72. doi: 10.1111/j.1755-148X.2011.00873.x
13. Garcia-Alvarez, A, Ortiz, C, and Munoz-Couselo, E. Current perspectives and novel strategies of NRAS-mutant melanoma. *Oncol Targets Ther*. (2021) 14:3709–19. doi: 10.2147/OTT.S278095
14. Randic, T, Kozar, I, Margue, C, Utikal, J, and Kreis, S. NRAS mutant melanoma: towards better therapies. *Cancer Treat Rev*. (2021) 99:102238. doi: 10.1016/j.ctrv.2021.102238
15. Zhao, J, Galvez, C, Beckermann, KE, Johnson, DB, and Sosman, JA. Novel insights into the pathogenesis and treatment of NRAS mutant melanoma. *Expert Rev Precis Med Drug Dev*. (2021) 6:281–94. doi: 10.1080/23808993.2021.1938545
16. Johnson, DB, Lovly, CM, Flavin, M, Panageas, KS, Ayers, GD, Zhao, Z, et al. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. *Cancer Immunol Res*. (2015) 3:288–95. doi: 10.1158/2326-6066.CIR-14-0207
17. Sadetsky, N, Lambert, P, Julian, C, Chen, J, and Yan, Y. Comprehensive genomic profiling and outcomes among metastatic melanoma patients (pts) treated with first-line cancer immunotherapy (CIT) in a real-world setting. *Ann Oncol*. (2019) 30:vii2. doi: 10.1093/annonc/mdz413.011
18. Kirchberger, MC, Ugurel, S, Mangana, J, Heppt, MV, Eigentler, TK, Berking, C, et al. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: results of a retrospective multicenter analysis of 364 patients. *Eur J Cancer*. (2018) 98:10–6. doi: 10.1016/j.ejca.2018.04.010
19. Guida, M, Bartolomeo, N, Quaglino, P, Madonna, G, Pigozzo, J, di Giacomo, A, et al. No impact of NRAS mutation on features of primary and metastatic melanoma or on outcomes of checkpoint inhibitor immunotherapy: an Italian melanoma intergroup (IMI) study. *Cancers*. (2021) 13:1–15. doi: 10.3390/cancers13030475
20. Covidence Systematic Review Software. Veritas health innovation (2017), Melbourne, Australia. Available at: [www.covidence.org](http://www.covidence.org). Accessed June 20, 2022.
21. Eisenhauer, EA, Therasse, P, Bogaerts, J, Schwartz, LH, Sargent, D, Ford, R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer*. (2009) 45:228–47. doi: 10.1016/j.ejca.2008.10.026
22. Wolchok, JD, Hoos, A, O'Day, S, Weber, JS, Hamid, O, Lebbé, C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. *Clin Cancer Res*. (2009) 15:7412–20. doi: 10.1158/1078-0432.CCR-09-1624
23. Oxford Centre for Evidence-Based Medicine. Levels of evidence (2009). Available at: <https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009>. Accessed June 20, 2022.
24. Wells, G, Shea, B, O'Connell, D, Peterson, JE, Welch, V, Losos, M, et al. *The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-analyses*. (2000). Ottawa Hospital Research Institute. Available at: [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp)
25. Duval, S, and Tweedie, R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics*. (2000) 56:455–63. doi: 10.1111/j.0006-341X.2000.00455.x
26. Egger, M, Davey Smith, G, Schneider, M, and Minder, C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. (1997) 315:629–34. doi: 10.1136/bmj.315.7109.629
27. Ascierto, PA, Simeone, E, Sileni, VC, Pigozzo, J, Maio, M, Altomonte, M, et al. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. *J Transl Med*. (2014) 12:116. doi: 10.1186/1479-5876-12-116
28. Lipson, EJ, Velculescu, VE, Pritchard, TS, Sausen, M, Pardoll, DM, Topalian, SL, et al. Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. *J Immunother Cancer*. (2014) 2:42. doi: 10.1186/s40425-014-0042-0
29. Johnson, DB, Frampton, GM, Rioth, MJ, Yusko, E, Xu, Y, Guo, X, et al. Targeted next generation sequencing identifies markers of response to PD-1 blockade. *Cancer Immunol Res*. (2016) 4:959–67. doi: 10.1158/2326-6066.CIR-16-0143
30. Jamal, R, Lapointe, R, Cocolakis, E, Thébault, P, Kazemi, S, Friedmann, JE, et al. Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma. *J Immunother Cancer*. (2017) 5:83. doi: 10.1186/s40425-017-0290-x
31. Afzal, MZ, Mercado, RR, and Shirai, K. Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma. *J Immunother Cancer*. (2018) 6:64. doi: 10.1186/s40425-018-0375-1
32. Dupuis, F, Lamant, L, Gerard, E, Torossian, N, Chaltiel, L, Filleron, T, et al. Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy article. *Br J Cancer*. (2018) 119:193–9. doi: 10.1038/s41416-018-0168-9
33. Sheng, X, Yan, X, Chi, Z, Si, L, Cui, C, Tang, B, et al. Axitinib in combination with toripalimab, a humanized immunoglobulin G 4 monoclonal antibody against programmed cell death-1, in patients with metastatic melanoma: an open-label phase Ib trial. *J Clin Oncol*. (2019) 37:2987–99. doi: 10.1200/JCO.19.00210
34. Loo, K, Gauvin, G, Soliman, I, Renzetti, M, Deng, M, Ross, E, et al. Primary tumor characteristics and next-generation sequencing mutations as biomarkers for melanoma immunotherapy response. *Pigment Cell Melanoma Res*. (2020) 33:878–88. doi: 10.1111/pcmr.12909
35. Tang, B, Chi, Z, Chen, Y, Liu, X, Wu, D, Chen, J, et al. Safety, efficacy, and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial. *Clin Cancer Res*. (2020) 26:4250–9. doi: 10.1158/1078-0432.CCR-19-3922

36. Byeon, S, Cho, HJ, Jang, KT, Kwon, M, Lee, J, and Kim, ST. Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment. *ESMO Open*. (2021) 6:100002. doi: 10.1016/j.esmoop.2020.100002
37. Li, JJ, Wang, JH, Dingy, Y, Li, DD, Wen, XZ, Zhao, JJ, et al. Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma. *J Cancer Res Clin Oncol*. (2021) 148:1159–69. doi: 10.1007/s00432-021-03700-9
38. Zhou, L, Wang, X, Chi, Z, Sheng, X, Kong, Y, Mao, L, et al. Association of NRAS mutation with clinical outcomes of anti-PD-1 monotherapy in advanced melanoma: a pooled analysis of four Asian clinical trials. *Front Immunol*. (2021) 12:691032. doi: 10.3389/fimmu.2021.691032
39. Zhang, WJ, Kong, YJ, Li, YT, Shi, F, Lyu, J, Sheng, C, et al. Novel molecular determinants of response or resistance to immune checkpoint inhibitor therapies in melanoma. *Front Immunol*. (2022) 12:12. doi: 10.3389/fimmu.2021.798474
40. Baujat, B, Mahe, C, Pignon, JP, and Hill, C. A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials. *Stat Med*. (2002) 21:2641–52. doi: 10.1002/sim.1221
41. Sterne, JA, Sutton, AJ, Ioannidis, JP, Terrin, N, Jones, DR, Lau, J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ*. (2011) 343:d4002. doi: 10.1136/bmj.d4002
42. Schünemann, H, Vist, G, Higgins, J, Santesso, N, Deeks, JJ, and Glasziou, P. Chapter 15: interpreting results and drawing conclusions In: J Higgins, J Thomas and J Chandler et al, editors. *Cochrane Handbook for Systematic Reviews of Interventions Version 6.1*. Cochrane: Wiley-Blackwell. (2020)
43. Hayward, NK, Wilmott, JS, Waddell, N, Johansson, PA, Field, MA, Nones, K, et al. Whole-genome landscapes of major melanoma subtypes. *Nature*. (2017) 545:175–80. doi: 10.1038/nature22071
44. Jamerson, T, Rebecca, VW, and Aguh, C. Genetic characteristics and response to systemic therapies of acral lentiginous melanoma at a tertiary care center—a retrospective review. *J Natl Med Assoc*. (2022) 114:7–11. doi: 10.1016/j.jnma.2021.08.034
45. Raval, NS, Hodges, WT, Ugwu-Dike, PO, Godoy, F, Anstas, G, Cornelius, LA, et al. Racial and socioeconomic differences in acral lentiginous melanoma outcomes: a Surveillance, epidemiology, and end results analysis. *J Am Acad Dermatol*. (2021) 87:866–7. doi: 10.1016/j.jaad.2021.11.023
46. Kailas, A, Dawkins, M, and Taylor, SC. Suggestions for increasing diversity in clinical trials. *JAMA Dermatol*. (2017) 153:727. doi: 10.1001/jamadermatol.2017.0850
47. Kamal, K, Imadojemu, S, and Charrow, A. Why diversity in dermatology clinical trials should no longer be optional: dismantling structural racism in dermatology. *JAMA Dermatol*. (2022) 158:353–4. doi: 10.1001/jamadermatol.2021.5190
48. Klempner, SJ, Fabrizio, D, Bane, S, Reinhart, M, Peoples, T, Ali, SM, et al. Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: a review of current evidence. *Oncologist*. (2020) 25:e147–59. doi: 10.1634/theoncologist.2019-0244
49. Wilmott, JS, Hersey, P, Long, GV, and Scolyer, RA. Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy? *Melanoma Manag*. (2015) 2:15–9. doi: 10.2217/mmt.14.26
50. Conway, JR, Kofman, E, Mo, SS, Elmarakeby, H, and Van Allen, E. Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. *Genome Med*. (2018) 10:93. doi: 10.1186/s13073-018-0605-7
51. Rose, AA, Armstrong, SM, Hogg, D, Butler, MO, Saibil, SD, Arteaga, DP, et al. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy. *J Immunother Cancer*. (2021) 9:e001642. doi: 10.1136/jitc-2020-001642
52. Yarchoan, M, Albacker, LA, Hopkins, AC, Montesion, M, Murugesan, K, Vithayathil, TT, et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. *JCI Insight*. (2019) 4:e126908. doi: 10.1172/jci.insight.126908
53. Hodi, FS, Wolchok, JD, Schadendorf, D, Larkin, J, Long, GV, Qian, X, et al. TMB and inflammatory gene expression associated with clinical outcomes following immunotherapy in advanced melanoma. *Cancer Immunol Res*. (2021) 9:1202–13. doi: 10.1158/2326-6066.CIR-20-0983
54. Jessurun, CAC, Vos, JAM, Limpens, J, and Luiten, RM. Biomarkers for response of melanoma patients to immune checkpoint inhibitors: a systematic review. *Front Oncol*. (2017) 7:233. doi: 10.3389/fonc.2017.00233
55. Jiang, J, Ding, Y, Wu, M, Chen, Y, Lyu, X, Lu, J, et al. Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma. *Cancer Med*. (2020) 9:8498–518. doi: 10.1002/cam4.3481
56. Cirenajwis, H, Lauss, M, Ekedahl, H, Törngren, T, Kvist, A, Saal, LH, et al. NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics. *Mol Oncol*. (2017) 11:438–51. doi: 10.1002/1878-0261.12050
57. Thielmann, CM, Chorti, E, Matull, J, Murali, R, Zarella, A, Lodde, G, et al. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors. *Eur J Cancer*. (2021) 159:113–24. doi: 10.1016/j.ejca.2021.09.035
58. Conway, JR, Dietlein, F, Taylor-Weiner, A, AlDubayan, S, Vokes, N, Keenan, T, et al. Integrated molecular drivers coordinate biological and clinical states in melanoma. *Nat Genet*. (2020) 52:1373–83. doi: 10.1038/s41588-020-00739-1
59. Shoushtari, AN, Chatila, WK, Arora, A, Sanchez-Vega, F, Kantheti, HS, Rojas Zamalloa, JA, et al. Therapeutic implications of detecting MAPK-activating alterations in cutaneous and unknown primary melanomas. *Clin Cancer Res*. (2021) 27:2226–35. doi: 10.1158/1078-0432.CCR-20-4189
60. Newell, F, Pires da Silva, I, Johansson, PA, Menzies, AM, Wilmott, JS, Addala, V, et al. Multiomic profiling of checkpoint inhibitor-treated melanoma: identifying predictors of response and resistance, and markers of biological discordance. *Cancer Cell*. (2022) 40:88–102.e7. doi: 10.1016/j.ccell.2021.11.012